Related Experiment Videos
Developing immunotherapeutic strategies for the control of Epstein-Barr virus-associated malignancies
D J Moss1, R Khanna, M Sherritt
1Epstein-Barr Virus Unit, University of Queensland and the Queensland Institute of Medical Research, Brisbane, Australia. denisM@qimr.edu.au
Abstract:
Epstein-Barr virus (EBV) infection is associated with various physical human malignancies. The potential for immunotherapeutic treatment by cytotoxic T cells (CTL) depends on the degree of EBV-antigen expression, with the best prospect revolving around the immunoblastic lymphomas of organ transplant patients in which adoptive transfer of in vitro reactivated CTL has already been demonstrated to be effective. Opportunities for effective immunotherapy in the treatment of nasopharyngeal carcinoma (NPC) is reduced because the available targets are limited to relatively nonimmunogenic proteins. However, analysis of NPC cells has revealed normal expression of the major histocompatibility complex (MHC)-encoded peptide transporters TAP-1 and TAP-2, together with high levels of human leukocyte antigen (HLA) class I alleles on the cell surface. Burkitt's lymphoma (BL) displays downregulated expression of MHC class I and TAP-1 and TAP-2 proteins, whereas viral antigen expression is limited to a protein incapable of processing class I CTL epitopes. It therefore seems likely that effective treatment of BL will revolve around protocols designed to reverse its undifferentiated phenotype.
Insights
Epstein-Barr virus (EBV) infection links to cancers. Immunotherapy shows promise for EBV-driven lymphomas, particularly in organ transplant patients, by using cytotoxic T cells (CTLs).
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Epstein-Barr virus (EBV) is linked to human malignancies.
- Immunotherapy using cytotoxic T cells (CTLs) is a potential treatment strategy.
- Treatment effectiveness depends on EBV-antigen expression levels and host immune response.
Purpose of the Study:
- To evaluate the potential for EBV-targeted immunotherapies across different malignancies.
- To analyze the expression of viral antigens and host immune factors in EBV-associated cancers.
- To identify optimal strategies for immunotherapy in nasopharyngeal carcinoma (NPC) and Burkitt's lymphoma (BL).
Main Methods:
- Analysis of EBV-antigen expression in various human cancers.
- Assessment of major histocompatibility complex (MHC) class I and peptide transporter (TAP-1, TAP-2) expression.
- Evaluation of cytotoxic T cell (CTL) epitope processing and presentation.
Main Results:
- Immunoblastic lymphomas in organ transplant patients show high EBV-antigen expression, making them suitable for adoptive CTL therapy.
- Nasopharyngeal carcinoma (NPC) has limited immunogenic targets but normal MHC class I, TAP-1, and TAP-2 expression.
- Burkitt's lymphoma (BL) exhibits downregulated MHC class I, TAP-1, and TAP-2, with viral antigens unsuitable for CTL epitope processing.
Conclusions:
- Adoptive CTL transfer is effective for EBV-driven lymphomas in immunocompromised patients.
- NPC immunotherapy is challenging due to limited viral targets, despite favorable antigen-presenting machinery.
- BL treatment may require strategies to reverse its undifferentiated phenotype and enhance immune recognition.